UA129339U - METHOD OF FORECASTING OSTEOARTHrosis DEVELOPMENT - Google Patents

Abstract

A method for predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, serum MTHFR C677T, eNOS T786C, thrombomodulin, osteocalcin, homocysteine, SRP, IL-6, and homozygous carrier 677-TT, 786-SSg and ml levels, ml and ml levels and ml levels, respectively, are determined in serum. ng / ml, homocysteine> 20 μmol / l, PSA> 6 mg / l, IL-6> 10 ng / l predict the development of osteoarthritis.

Description

The proposed useful model - a method of predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, examination of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. M., 2001. - vol. 2. - pp. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, prevention of its development and possible complications caused by the internal characteristics of the body.

The basis of a useful model is the task of developing a method that will allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, according to a useful model, the polymorphism of methylenetetrahydrofolate reductase (MTNEK C677T), nitric oxide synthase (emo T786C), content of thrombomodulin, osteocalcin, homocysteine, C-reactive protein is determined in the patient's blood serum ( SRP), interleukin 6 (IL-6). With homozygous carriers of 677-HT, 786-SS, levels of thrombomodulin "5 ng/ml, osteocalcin "21 ng/ml, homocysteine 220 μmol/l, SRP "6 mg/l, IL-6 "10 ng/l predict the development of osteoarthritis .

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the MTNEK C677tT, emo T786C gene polymorphism is determined, the content of thrombomodulin, osteocalcin, homocysteine, SRP, IL-6 is determined by the immunoenzymatic method. With homozygous carrier 677-177, 786-SS, levels of thrombomodulin "5 ng/ml, osteocalcin "21 ng/ml, homocysteine 220 μmol/l,

SRP »6 mg/l, IL-6 »10 ng/l predict the development of osteoarthritis.

A specific example of using the method.

Patient T., 59 years old, was hospitalized in the clinic due to pain syndrome in the right hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. Polymorphisms of MTNEK C677T and emo5 T786C genes were determined in blood serum. The content of thrombomodulin, osteocalcin, homocysteine, SRP, 1IL-b was determined by immunoenzymatic method.

A homozygous carrier of 677-TT and 786-SS was established, thrombomodulin levels - 12 ng/ml,

From osteocalcin - 16 ng/ml, homocysteine - 32 μmol/l, SRP - 13 mg/l, IL-6-21 ng/l. The development of osteoarthritis was diagnosed. After 13 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination, X-ray photography, which is distinguished by the fact that the polymorphism of MT'NEK c677T, eMmo5 T786C genes, the content of thrombomodulin, osteocalcin, homocysteine, SRP, IL-6 are determined in blood serum, and homozygous carrier 677-TT, 786-SS and levels of thrombomodulin "5 ng/ml, osteocalcin "21 ng/ml, homocysteine 220 μmol/l, SRP 2b mg/l, IL-b6 "10 ng/l predict the development of osteoarthritis.